BioNTech Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Ugur Sahin

Chief executive officer

€11.6m

Total compensation

CEO salary percentage	3.1%
CEO tenure	15yrs
CEO ownership	17.1%
Management average tenure	9yrs
Board average tenure	10yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ugur Sahin's remuneration changed compared to BioNTech's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2022	n/a	n/a	€10b
Jun 30 2022	n/a	n/a	€12b
Mar 31 2022	n/a	n/a	€13b
Dec 31 2021	€12m	€360k	€10b
Sep 30 2021	n/a	n/a	€7b
Jun 30 2021	n/a	n/a	€4b
Mar 31 2021	n/a	n/a	€1b
Dec 31 2020	€17m	€360k	€15m
Sep 30 2020	n/a	n/a	-€410m
Jun 30 2020	n/a	n/a	-€230m
Mar 31 2020	n/a	n/a	-€192m
Dec 31 2019	€7m	€311k	-€179m
Sep 30 2019	n/a	n/a	-€122m
Jun 30 2019	n/a	n/a	-€116m
Mar 31 2019	n/a	n/a	-€77m
Dec 31 2018	€653k	€210k	-€48m

Compensation vs Market: Ugur's total compensation ($USD12.50M) is above average for companies of similar size in the BG market ($USD4.12M).

Compensation vs Earnings: Ugur's compensation has been consistent with company performance over the past year.

CEO

Ugur Sahin (57 yo)

15yrs

Tenure

€11,586,000

Compensation

Prof. Ugur Sahin, MD, is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its Member of Management Board and serves as its Chair of the Management Board. Prof. Sahin co-Fo...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ugur Sahin	Co-Founder	15yrs	€11.59m	17.08% € 5.5b
Ozlem Tureci	Co-Founder	no data	€1.13m	no data
Christoph Huber	Co-Founder & Member of Supervisory Board	15yrs	€59.00k	0.82% € 265.6m
Jens Holstein	CFO & Member of Management Board	1.5yrs	€1.68m	no data
Sierk Poetting	MD, COO & Member of Management Board	no data	€2.69m	0.00069% € 222.5k
Ryan Richardson	Chief Strategy Officer	3yrs	€1.13m	0.0019% € 603.0k
Sean Marett	Chief Business Officer	no data	€2.48m	0.29% € 93.7m
Sylke Maas	Vice President of Investor Relations and Business Strategy	no data	no data	no data
James Timothy Ryan	Senior VP & General Counsel	no data	no data	no data
Michael Boehler	MD & Head of Global External Communications	no data	no data	no data
Katalin Kariko	Senior VP & Head of RNA Protein Replacement	no data	no data	no data
Oliver Hennig	Senior Vice President of Operations	no data	no data	no data

9.0yrs

Average Tenure

57yo

Average Age

Experienced Management: 22UA's management team is seasoned and experienced (9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Christoph Huber	Co-Founder & Member of Supervisory Board	15yrs	€59.00k	0.82% € 265.6m
Rolf Zinkernagel	Member of Scientific Advisory Board	no data	no data	no data
Rudolf Staudigl	Supervisory Board Member	less than a year	no data	no data
Hans Hengartner	Member of Scientific Advisory Board	no data	no data	no data
Ulrich Wandschneider	Independent Deputy Chairman Supervisory Board	5yrs	€112.00k	no data
Michael Motschmann	Independent Supervisory Board Member	15yrs	€63.00k	no data
Helmut Jeggle	Independent Supervisory Board Chairman	15yrs	€181.00k	0.14% € 44.1m
Anja Morawietz	Supervisory Board Member	less than a year	no data	no data

10.0yrs

Average Tenure

66.5yo

Average Age

Experienced Board: 22UA's board of directors are seasoned and experienced ( 10 years average tenure).

BioNTech Management

Management criteria checks 3/4

Key information

Recent management updates

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

BioNTech SE, Annual General Meeting, May 17, 2024

BioNTech Appoints James Ryan as Chief Legal Officer Effective September 1, 2023

BioNTech SE Approves Board Appointments

Recent updates

BioNTech SE Reiterates Revenue Guidance for the Full Year 2024

BioNTech SE to Report Q1, 2024 Results on May 06, 2024

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast Cancer

Robbins LLP Informs Investors of Class Action Filed Against BioNTech SE

BioNTech and Duality Biologics (Suzhou) Co. Ltd. Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Endometrial Cancer

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Aexerna Therapeutics.

BioNTech SE to Report Q4, 2023 Results on Mar 20, 2024

Pfizer Inc. and BioNTech SE Announce Positive Topline Data for MRNA-Based Combination Vaccine Program Against Influenza and Covid-19

BioNTech SE, Annual General Meeting, May 17, 2024

BioNTech SE Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-Based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

Curevac Reports Progress in Intellectual Property Infringement Case Against Biontech in Germany

Pfizer and Biontech Receive Health Canada Authorization for Xbb.1.5-Adapted Monovalent Covid-19 Vaccine

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

BioNTech Appoints James Ryan as Chief Legal Officer Effective September 1, 2023

BioNTech SE to Report Q3, 2023 Results on Nov 06, 2023

BioNTech SE acquired remaining stake in InstaDeep Ltd for approximately £430 million.

BioNTech SE to Report Q2, 2023 Results on Aug 07, 2023

BioNTech SE and OncoC4, Inc. Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC

BioNTech SE Provides Revenue Guidance for the Full Year 2023

BioNTech SE Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165

BioNTech SE Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

Pfizer and BioNTech SE Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Children 5 Through <12 Years of Age

BioNTech SE and Pfizer Inc. Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-adapted bivalent COVID-19 Vaccine in Children Under 5 years

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

Pfizer Inc. and BioNTech SE Advances Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T Cell Responses and Duration of Protection

Pfizer and Biontech Receive Positive Chmp Opinion for Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union

BioNTech SE Se Revises Its Earnings Guidance for the Full Year 2022

Pfizer Inc. and BioNTech SE Announces Updated Clinical Data for Omicron Ba.4/Ba.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

Pfizer and Biontech Receive Positive CHMP Opinion for Comirnaty® in Children 6 Months to Less Than 5 Years in the European Union

Pfizer and BioNTech Announce Positive Early Data from Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age

Pfizer Canada ULC and BioNTech SE's Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Individuals 12 Years of Age and Older

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

Pfizer Inc. and BioNTech SE Receive Positive Chmp Opinion for Conversion of Comirnaty® Conditional Marketing Authorization to Full Marketing Authorization in the European Union

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster in European Union

Biontech Presents Encouraging Phase 1/2 Follow-Up Data for Car-T Candidate Bnt211 in Hard-To-Treat Solid Tumors At ESMO

Pfizer Inc. and BioNTech SE Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union

Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine

Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months Through 4 Years of Age

Pfizer and Biontech Submits Application to U.S. FDA for Emergency Use Authorization of Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine

BioNTech Reiterates Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings released: EPS: €6.88 (vs €11.42 in 2Q 2021)

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy with Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design

Pfizer Inc. and BioNTech SE Submits Variation to the European Medicines Agency

Pfizer and BioNTech Announce U.S. FDA Approval of their COVID-19 Vaccine Comirnaty for Adolescents 12 Through 15 Years of Age

CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech

Investor sentiment improved over the past week

Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron

BioNTech SE Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support of CAR-T Candidate BNT211 in Testicular Cancer

Pfizer and BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age

BioNTech SE Announces Positive Phase 1 Data from MRNA-Based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer Presented At ASCO

BioNTech SE Approves Board Appointments

Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose

BioNTech SE and Pfizer Inc. Announces the U.S. Food and Drug Administration Expands Emergency Use Authorization

Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with European Commission

Now 21% undervalued

BioNTech SE Reiterates Earnings Guidance for the Year 2022

First quarter 2022 earnings released: EPS: €15.13 (vs €4.64 in 1Q 2021)

BioNTech SE Reiterates Earnings Guidance for the Year 2022

BioNTech SE announced that it has received $149.999985 million in funding from Pfizer Inc.

BioNTech Presents Positive Preliminary Phase 1/2 Data for First-In-Class CAR-T Program BNT211 at AACR

Now 21% undervalued after recent price drop

Full year 2021 earnings released: EPS: €42.18 (vs €0.065 in FY 2020)

BioNTech SE (NasdaqGS:BNTX) announces an Equity Buyback for $1,500 million worth of its shares.

BioNTech SE Proposes Special Cash Dividend

Investor sentiment improved over the past week